-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
HC Wainwright Trims Imago BioSciences (NASDAQ:IMGO) Target Price to $35.00
HC Wainwright Trims Imago BioSciences (NASDAQ:IMGO) Target Price to $35.00
Imago BioSciences (NASDAQ:IMGO – Get Rating) had its price objective cut by HC Wainwright from $36.00 to $35.00 in a research report released on Tuesday, MarketBeat reports. They currently have a buy rating on the stock.
Imago BioSciences Stock Down 0.8 %
Shares of Imago BioSciences stock opened at $19.09 on Tuesday. Imago BioSciences has a 12-month low of $11.56 and a 12-month high of $35.68. The stock has a market cap of $644.10 million and a P/E ratio of -10.72. The business's 50 day moving average is $15.43 and its 200-day moving average is $17.73.
Get Imago BioSciences alerts:Insider Activity at Imago BioSciences
In related news, insider Jennifer Peppe sold 5,598 shares of the stock in a transaction on Monday, August 15th. The stock was sold at an average price of $19.41, for a total value of $108,657.18. Following the sale, the insider now owns 148,809 shares in the company, valued at approximately $2,888,382.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have sold 7,721 shares of company stock worth $147,356. Company insiders own 14.90% of the company's stock.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. FMR LLC grew its position in Imago BioSciences by 4.4% in the second quarter. FMR LLC now owns 5,060,365 shares of the company's stock valued at $67,759,000 after acquiring an additional 212,359 shares during the last quarter. BlackRock Inc. lifted its stake in Imago BioSciences by 146.2% in the first quarter. BlackRock Inc. now owns 3,290,894 shares of the company's stock valued at $63,415,000 after buying an additional 1,954,112 shares during the period. Frazier Life Sciences Management L.P. acquired a new position in Imago BioSciences in the first quarter valued at approximately $57,256,000. Citadel Advisors LLC increased its holdings in shares of Imago BioSciences by 0.7% during the second quarter. Citadel Advisors LLC now owns 2,517,041 shares of the company's stock valued at $33,703,000 after acquiring an additional 18,620 shares in the last quarter. Finally, Woodline Partners LP increased its holdings in shares of Imago BioSciences by 101.9% during the fourth quarter. Woodline Partners LP now owns 848,129 shares of the company's stock valued at $20,109,000 after acquiring an additional 428,127 shares in the last quarter. Institutional investors own 88.28% of the company's stock.About Imago BioSciences
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
See Also
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Is Sanofi A Buy, Despite Recent Stumbles?
- If You Hate Speed Cameras, Then You'll Like Verra Mobility Stock
- Institutional Support For TJX Companies May Cap Gains
- Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
- BJ's Wholesale Club Pops, Will Costco Be Next?
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Imago BioSciences (NASDAQ:IMGO – Get Rating) had its price objective cut by HC Wainwright from $36.00 to $35.00 in a research report released on Tuesday, MarketBeat reports. They currently have a buy rating on the stock.
据MarketBeat报道，在周二发布的一份研究报告中，云莱特将Imago BioSciences(纳斯达克代码：IMGO-GET)的目标价从36.00美元下调至35.00美元。他们目前对该股的评级为买入。
Imago BioSciences Stock Down 0.8 %
Imago BioSciences股价下跌0.8%
Shares of Imago BioSciences stock opened at $19.09 on Tuesday. Imago BioSciences has a 12-month low of $11.56 and a 12-month high of $35.68. The stock has a market cap of $644.10 million and a P/E ratio of -10.72. The business's 50 day moving average is $15.43 and its 200-day moving average is $17.73.
Imago BioSciences的股票周二开盘报19.09美元。Imago BioSciences的股价为11.56美元，为12个月低点，12个月高位为35.68美元。该股市值为6.441亿美元，市盈率为-10.72倍。该业务的50日移动均线切入位在15.43美元，200日移动均线切入位在17.73美元。
Insider Activity at Imago BioSciences
Imago BioSciences的内部活动
In related news, insider Jennifer Peppe sold 5,598 shares of the stock in a transaction on Monday, August 15th. The stock was sold at an average price of $19.41, for a total value of $108,657.18. Following the sale, the insider now owns 148,809 shares in the company, valued at approximately $2,888,382.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have sold 7,721 shares of company stock worth $147,356. Company insiders own 14.90% of the company's stock.
在相关新闻中，内部人士珍妮弗·佩佩在8月15日星期一的一次交易中出售了5598股该股。这只股票的平均售价为19.41美元，总价值为108,657.18美元。出售后，这位内部人士现在拥有该公司148,809股，价值约2,888,382.69美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过这个超链接访问该文件。在上个季度，内部人士出售了7721股公司股票，价值147,356美元。公司内部人士持有该公司14.90%的股份。
Institutional Inflows and Outflows
机构资金流入和流出
About Imago BioSciences
关于Imago BioSciences
(Get Rating)
(获取评级)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
临床阶段生物制药公司Imago BioSciences，Inc.发现和开发了针对赖氨酸特异性脱甲基酶1(LSD1)的小分子产品候选产品，LSD1是一种用于生产骨髓中血细胞的酶。它的主要候选产品是Bomedemstat，正在进行第二阶段临床试验，用于治疗骨髓增生性肿瘤和慢性骨髓癌，如骨髓纤维化、原发性血小板增多症和真性红细胞增多症。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Is Sanofi A Buy, Despite Recent Stumbles?
- If You Hate Speed Cameras, Then You'll Like Verra Mobility Stock
- Institutional Support For TJX Companies May Cap Gains
- Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
- BJ's Wholesale Club Pops, Will Costco Be Next?
- 免费获取StockNews.com关于Imago BioSciences(IMGO)的研究报告
- 尽管赛诺菲最近跌跌撞撞，但它是买入的吗？
- 如果你讨厌超速摄像头，那么你会喜欢Verra Mobility Stock
- 对TJX公司的机构支持可能限制涨幅
- 星巴克股票，品牌忠诚度足以成为购买理由吗
- BJ‘s批发俱乐部流行音乐，Costco会是下一个吗？
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Imago生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Imago BioSciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧